CYP2D6 and depressive symptom measurement: The present study provides referential data for clinicians regarding the safety of initiation of CYP2D6-metabolized opioids on existing antidepressants (i.e., opioid-triggered interaction), which was predominantly used by older nursing home residents for treating their comorbid depression and chronic pain.